What is aTyr Pharma's D&A?

aTyr Pharma (ATYR) reported D&A of $162K in Q1 2026.

How has aTyr Pharma's D&A changed year-over-year?

aTyr Pharma's D&A decreased by 3.0% year-over-year, from $167K to $162K.

What is the long-term trend for aTyr Pharma's D&A?

Over 4 years (2021 to 2025), aTyr Pharma's D&A has grown at a 8.7% compound annual growth rate (CAGR), from $475K to $664K.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

aTyr Pharma ATYR D&A

D&A at other companies

Bristol-Myers SquibbBMY

$594M-41.3%

United TherapeuticsUTHR

$22.6M+14.1%

Design Therapeutics, Inc.DSGN

$157K-1.3%

Vor BiopharmaVOR

$28K-96.6%

Oric Pharmaceuticals, Inc.ORIC

$270K-10.6%

Rigel PharmaceuticalsRIGL

$597K-1.2%

Other financials

Income statement

See full

Revenue-—

Operating income-$11.4M+27.5%

Net income-$10.8M+27.5%

EPS (diluted)-$0.11+35.3%

Balance sheet

See full

Cash & equivalents$10.0M-3.4%

Total debt$12.3M-9.2%

Total equity$57.9M-22.8%

Total assets$79.7M-18.1%

Cash flow

See full

Operating cash flow-$12.5M+18.8%

CapEx$138.0K—

Free cash flow-$12.7M+17.9%

Valuation

See full

Market cap$54.88M-88.2%

Enterprise value$57.17M—

P/S288.8×—

Profitability

See full

Operating margin-40,856.3%+28,833pp

Net margin-39,009.5%+29,653pp

FCF margin-32,664.7%+4,018pp

Returns & leverage

See full

Return on equity-105.3%+50.6pp

Debt / equity0.2×0.0×

Current ratio5.8×-2.0×

Where this comes from

Reported directly by aTyr Pharma in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is aTyr Pharma's D&A?: aTyr Pharma (ATYR) reported D&A of $162K in Q1 2026.
How has aTyr Pharma's D&A changed year-over-year?: aTyr Pharma's D&A decreased by 3.0% year-over-year, from $167K to $162K.
What is the long-term trend for aTyr Pharma's D&A?: Over 4 years (2021 to 2025), aTyr Pharma's D&A has grown at a 8.7% compound annual growth rate (CAGR), from $475K to $664K.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.